Cargando…
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091104/ https://www.ncbi.nlm.nih.gov/pubmed/36691995 http://dx.doi.org/10.1002/cac2.12401 |
| _version_ | 1785023085809762304 |
|---|---|
| author | Shaurova, Tatiana Yan, Lingyue Su, Yafei Rich, Laurie James Vincent‐Chong, Vui King Calkins, Hannah Pokharel, Saraswati Petkovich, Martin Seshadri, Mukund Wu, Yun Hershberger, Pamela Anne |
| author_facet | Shaurova, Tatiana Yan, Lingyue Su, Yafei Rich, Laurie James Vincent‐Chong, Vui King Calkins, Hannah Pokharel, Saraswati Petkovich, Martin Seshadri, Mukund Wu, Yun Hershberger, Pamela Anne |
| author_sort | Shaurova, Tatiana |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10091104 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100911042023-04-13 A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer Shaurova, Tatiana Yan, Lingyue Su, Yafei Rich, Laurie James Vincent‐Chong, Vui King Calkins, Hannah Pokharel, Saraswati Petkovich, Martin Seshadri, Mukund Wu, Yun Hershberger, Pamela Anne Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2023-01-24 /pmc/articles/PMC10091104/ /pubmed/36691995 http://dx.doi.org/10.1002/cac2.12401 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Shaurova, Tatiana Yan, Lingyue Su, Yafei Rich, Laurie James Vincent‐Chong, Vui King Calkins, Hannah Pokharel, Saraswati Petkovich, Martin Seshadri, Mukund Wu, Yun Hershberger, Pamela Anne A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title | A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title_full | A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title_fullStr | A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title_full_unstemmed | A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title_short | A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer |
| title_sort | nanotherapeutic strategy to target drug‐tolerant cells and overcome egfr tyrosine kinase inhibitor resistance in lung cancer |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091104/ https://www.ncbi.nlm.nih.gov/pubmed/36691995 http://dx.doi.org/10.1002/cac2.12401 |
| work_keys_str_mv | AT shaurovatatiana ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT yanlingyue ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT suyafei ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT richlauriejames ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT vincentchongvuiking ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT calkinshannah ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT pokharelsaraswati ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT petkovichmartin ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT seshadrimukund ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT wuyun ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT hershbergerpamelaanne ananotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT shaurovatatiana nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT yanlingyue nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT suyafei nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT richlauriejames nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT vincentchongvuiking nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT calkinshannah nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT pokharelsaraswati nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT petkovichmartin nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT seshadrimukund nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT wuyun nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer AT hershbergerpamelaanne nanotherapeuticstrategytotargetdrugtolerantcellsandovercomeegfrtyrosinekinaseinhibitorresistanceinlungcancer |